Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Placebo-controlled Trial of Antiretroviral Therapy (ART) Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs) vs ART Plus Placebo During Primary HIV-1 Infection to Study the Impact on Post-treatment HIV Control.

NCT05300035 is registered in ClinicalTrials.gov with ANRS, Emerging Infectious Diseases as lead sponsor.

NCT NCT05300035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05300035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Placebo-controlled Trial of Antiretroviral Therapy (ART) Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs) vs ART Plus Placebo During Primary HIV-1 Infection to Study the Impact on Post-treatment HIV Control.
Lead sponsor
ANRS, Emerging Infectious Diseases
Phase
Phase 2
Overall status
Recruiting
Start date
April 11, 2024
Completion date
December 10, 2028
Enrollment
69 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hiv/aids and infections